Male and female Fischer 344 rats and B6C3F1 mice (10/sex/ dose group) were given 0, 5, 15, 50, or 100 mg/kg/day (rats) or 0, 15, 50, 100, or 175 (mice) mg/kg/day racemic 1,3-dichloropropene (1,3-D), respectively, via their diets for 13 weeks. Satellite groups of rats (recovery = 10 rats/sex/group) ingesting 0 or 100 mg/kg/ day 1,3-D were provided control feed for an additional 4 weeks to examine recovery. The test material was stabilized in the feed by microencapsulation in a starch/sucrose matrix (80/20). The body weights of male and female rats ingesting 3=5 and s=15 mg/kg/ day, respectively, and of all treatment groups of mice were decreased relative to controls. The terminal body weights of high dose group rats and mice were decreased approximately 13-16%. A number of changes in serum biochemical parameters and decreases in organ weights accompanied the depressed body weights of these animals. Histologically, the only treatment-related change observed was a slight degree of basal cell hyperplasia and hyperkeratosis in the nonglandular portion of the stomachs of a majority of male and female rats ingesting 3=15 mg/kg/day. After the 4-week recovery period, most treatment-related changes were noted to be reversible in nature. No treatment-related histopathological changes were observed in the tissues of treated mice. Based upon relatively slight depressions in body weights at the lowest dosages tested, the no-observed-adverse-effect levels for male rats and both sexes of mice were determined to be 5 mg/kg/day and 15 mg/kg/ day, respectively. A no-observed-effect level of 5 mg/kg/day was established for female rats, c i 1,3-Dichloropropene (1,3-D) has been utilized as a soil fumigant over the last 50 years for the control of nematodes in a number of agricultural applications. As reviewed by Torkelson (1994), 1,3-D has an LD50 in Fischer 344 rats of 220-300 mg/kg, is a moderate dermal irritant when applied (occluded) to the shaved backs of rabbits, and causes marked redness and chemosis when instilled in the eyes of rabbits. Most repeated-dose toxicity data on 1,3-D in experimental animals have been generated using the inhalation route of administration due to its high vapor pressure.
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Several inhalation toxicity studies of relatively high purity 1,3-D formulations have been conducted in Fischer 344 rats and B6C3F1 mice. The respiratory and olfactory epithelia of the nasal mucosa of both rats and mice were observed to undergo degeneration and/or hyperplasia when exposed tô 30 and >90 ppm vapor, respectively, 6 hr/day, 5 days/ week, for 13 weeks (Stott et al, 1988) . In addition, hyperplasia of the transitional epithelium of the urinary bladder was observed in female mice exposed to 3*90 ppm vapor. Under a similar exposure regimen, the chronic inhalation of 5^20 ppm 1,3-D vapors by Fischer 344 rats and B6C3F1 mice also resulted in degeneration and/or hyperplasia of nasal mucosa (Lomax et al, 1989) . In addition, hyperplasia of the urinary bladder and forestomach epithelia and changes consistent with decreased hepatocellular glycogen and lipid content of renal tubular cells were observed in one or both sexes of mice inhaling 20 and/or 60 ppm vapor. The only neoplastic response observed was an increased incidence of benign lung tumors in high exposure group male mice. The limited repeated exposure oral toxicity data which have been generated on 1,3-D have suffered from the use of outdated product formulations and bolus dosing (gavage) techniques, the latter dictated by the relatively high volatility and potential instability of 1,3-D. Til et al. (1973) administered up to 30 mg/kg/day of a relatively impure formulation of 1,3-D (78% purity) to Wistar rats via gavage, 6 days/week, for 13 weeks. Liver weights of male and female Wistar rats administered > 10 and 30 mg/ kg/day dosages, respectively, were elevated. No histopathological changes accompanied the organ weight changes. Chronic oral gavage of a higher purity (approx. 90%) formulation of 1,3-D, stabilized with epichlorohydrin, in rats and mice resulted in a number of tumorigenic and nontumorigenic effects (NTP, 1985; Yang et al, 1986) . Benign and/or malignant tumors of the forestomach and liver were observed in rats administered 25 and/or 50 mg/kg/day 1,3-D. Tumors of the forestomach, urinary bladder, and, possibly, the liver were also observed in female mice administered 50 and/or 100 mg/kg/day 1,3-D.
The present studies were undertaken to provide subchronic oral toxicity data on 1,3-D in rats and mice utilizing a more recent 1,3-D formulation and a nonbolus oral dosing methodology. These studies were conducted following global Good Laboratory Practice Guidelines.
MATERIALS AND METHODS

Test substance.
1,3-D, obtained from DowElanco, Indianapolis, Indiana, as TELONEII soil fumigant, was microencapsulated in a starch/sucrose matrix (80/20%) by Midwest Research Institute (MRI), (Kansas City, MO). Particle size ranged from 100 to 400 fim. The liquid 1,3-D submitted to MRI for microencapsulation was determined to have a chemical purity of 95.8% (50.7% cis; 45.1% trans) via gas chromatography/infrared spectroscopy. The microencapsulated 1,3-D, received from MRI, was determined both gravimetrically and analytically to have a percentage loading of approximately 40% w/w and a composition nearly identical to that of the original material. Microspheres containing no 1,3-D (placebo) were also provided by MRI.
Animals. Male and female Fischer 344 rats and B6C3F1 mice, 6-8 weeks of age at study start, were purchased from Charles River Research Laboratories (Portage, MI for mice and Kingston, NY for rats) and were utilized for this study. Upon arrival at the laboratory, 2 the animals were examined by the laboratory veterinarian and were acclimated to the laboratory environment for at least 7 days prior to the initiation of dosing. The animals were assigned to control and dose groups using a computerized randomization program based on body weights. Animals were uniquely identified via an implanted microchip (Biomedic Data Systems, Inc., Maywood, NJ). All animals were individually housed in stainless steel cages in rooms designed to maintain adequate environmental conditions (22°C, 50% RH, 12-h photocycle). Cages contained a feed crock and a pressure-activated nipple-type watering system. The animals were provided Purina Certified Rodent Chow 5002 (Purina Mills, Inc., St. Louis, MO), which served as the vehicle for the microencapsulated 1,3-D, and tap water ad libitum.
Dosage levels. Groups of rats and mice (10/dose/sex) were administered the test substance via their diets for a 13-week period. The targeted dose levels for the study were 0 (control), 5, 15, 50, or 100 mg/kg/day 1,3-D for rats and 0 (control), 15, 50, 100, or 175 mg/kg/day 1,3-D for mice. Placebo microspheres were added to rodent chow and served as the control. In addition, satellite groups of 10 rats/sex were provided 0 or 100 mg/kg/ day for 13 weeks, followed by a 4-week recovery period during which time all animals were provided control rodent chow. These groups of animals were used to examine the reversibility of any treatment-related effects observed following 13 weeks of dosing.
Diet preparation.
Diets were prepared by serially diluting the microencapsulated 1,3-D with rodent feed. Initial concentrations of 1,3-D in the diet were calculated from prestudy body weights and feed consumption data. Subsequently, the concentrations of the test material in the feed were adjusted weekly based upon the most recent body weight and feed consumption data. The placebo microspheres were mixed with rodent feed to serve as an appropriate control. The amount of starch/sucrose microspheres added to the feed of control animals was approximately equivalent to the amount of starch/sucrose added to the high dose diets. Stability, homogeneity, and concentration analyses were conducted during the study.
In-life data. Animals were carefully examined each day for signs of toxicity. In addition, a weekly clinical examination was conducted on all animals which included a detailed, hands-on examination. Body weights and feed consumption data were collected and calculated, respectively, for all rats and mice twice during the prestudy period and then weekly during the dosing and recovery (rats only) periods.
Clinical pathology.
Urinalysis (rats only), clinical chemistry, and hematological evaluations were conducted on all rats and mice. In rats, param-eters identified as significantly different than controls during the 13-week study were also evaluated in the recovery group rats following the 4-week recovery period. Urine samples for rats were collected from nonfasted animals during the week prior to the scheduled necropsy. Urine pH, bilirubin, glucose, protein, ketone, occult blood and urobilinogen content, specific gravity, color, and appearance were determined using a Clinitek 200 urine chemistry analyzer (Ames Division, Miles Laboratory, Elkhart, IN) and a Goldberg Refractometer (American Optical Company, Instrument Division, Buffalo, NY).
Blood samples were collected during the scheduled necropsies. The animals were anesthetized with methoxyflurane and blood samples were obtained via puncture of the orbital sinus. Hematology samples were mixed with EDTA and blood smears were prepared and stained with Wright's stain. Hematocrit, hemoglobin concentration, erythrocyte count, total leukocyte count, and platelet count were determined using an ELT-8 (Ortho Instruments, Westwood, MA). Leukocyte differential counts were conducted manually and erythrocyte, leukocyte, and platelet morphology were evaluated.
Blood samples for clinical chemistry determinations were held on ice and the serum was harvested. Enzyme activities of alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, creatine phosphokinase (rat only), and concentrations of urea nitrogen, creatinine, total protein, albumin, globulin (calculated), glucose, total bilirubin, electrolytes (Na, K, P, Cl, Ca), cholesterol, and triglycerides were determined using a Monarch 2000 chemistry analyzer (Instrument Laboratories, Lexington, MA).
Anatomic pathology. Rats and mice were anesthetized with methoxyflurane, the tracheas were exposed and clamped, and the animals were euthanized by decapitation. Terminal body weights (rats, fasted; mice, nonfasted) were recorded for all animals at the scheduled necropsy. Brain, liver, kidneys, heart, adrenals (rats only), and testes or ovaries (rats only) were weighed and organ-to-body weight ratios calculated.
A complete gross examination of tissues was conducted on all animals. The nasal cavity was flushed and the lungs distended to an approximately normal inspiratory volume with neutral, phosphate-buffered 10% formalin. In addition, the urinary bladder was moderately distended with neutral, phosphate-buffered 10% formalin. Representative samples of over 65 tissues from each animal were collected and preserved in formalin solution.
All preserved tissues from control and high dose group animals were processed by standard procedures and embedded in paraffin. Tissues were sectioned at approximately 6 ^m, stained with hematoxylin and eosin, and examined by light microscopy by a veterinary pathologist The lungs, liver, kidneys, stomach, mesenteric tissues (female rats only), any tissues having grossly observable lesions, and any target tissues were processed and examined from intermediate and low dose group animals. Potential target tissues identified following 13 weeks, kidneys, liver, stomach, and mesenteric tissues, were examined histologically from recovery group rats.
Statistics. Descriptive statistics (means and standard deviations) were reported for feed consumption, leukocyte differential counts, and nucleated erythrocyte counts. Body weights, organ weights, clinical chemistry data, appropriate hematologic data, and urinary specific gravity were evaluated by Bartlett's test (a = 0.01; Winer, 1971) for equality of variances. Based on the outcome of Bartlett's test, exploratory data analysis was performed by a parametric (a = 0.10; Steel and Tome, 1960) or nonparametric (a = 0.10; Hollander and Wolfe, 1973) analysis of variance (ANOVA), followed respectively by Dunnett's test (a = 0.05, two sided; Winer, 1971) or the Wilcoxon rank-sum test (a = 0.05, two sided; Hollander and Wolfe, 1973) with a Bonferroni correction (Miller, 1966) for multiple comparisons.
RESULTS
Dosing.
The microcapsule technology used in this study was developed by MRI to provide a means by which volatile, reactive, or unpalatable chemicals can be administered to Antemortem data. There were no treatment-related clinical signs of toxicity noted in rats or mice at any dose level over the course of the study. Body weight data are presented in Figs. 1 and 2 . A dose-related, statistically identified depression in body weights (6-16%) was observed in male rats ingesting dosages of 5=5 mg/kg/day and female rats (5-11%) ingesting 5*15 mg/kg/day, respectively, relative to control values. Following the 4-week recovery period, the body weights of high dose males and females were only 11.4 and 8.7% lower than controls, indicating some recovery. Body weights of male and female mice ingesting dosages of 5= 15 mg/kg/day were depressed in a dose-related manner at the termination of the study by 5-15 and 5-13%, respectively.
Feed consumption was consistently decreased for high dose group male and female rats and occasionally depressed at lower dosages relative to control values during the 13 weeks of dosing (Figs. 3a and 3b) . By the end of the 4-week recovery period, high dose level rats ingested amounts of feed approximately equivalent to those of control rats. Feed consumption by treated mice was relatively unchanged and only occasionally identified as depressed at the higher dose levels relative to controls during the study (data not shown).
Clinical pathology. There were no treatment-related changes identified in any urinalysis parameters measured in treated rats following 13 weeks. The only statistically identified changes observed in hematological parameters in either species tested were increases in the platelet count of male rats ingesting 3=50 mg/kg/day and a decrease in the white blood cell count of male mice ingesting 175 mg/kg/ day (Table 1) ; however, these changes were not dose-related and/or lacked a histopathologic correlate. No treatment-related changes in WBC differential counts were noted in any treatment groups of animals (data not shown). PLAT counts had returned to control values following the 4-week recovery period (Table 1) .
Also shown in Table 1 , statistically identified differences in clinical chemistry parameters were limited to slight decreases in serum alkaline phosphatase (5=50 mg/kg/day), triglyceride levels (s= 15 mg/kg/day), and increased cholesterol levels (high dose) in male rats and minimal decreases in the total protein, albumin, and globulin levels in 50 and/or 100 mg/kg/day dose group females. Following a 4-week recovery period, most values had returned to near control levels though several were still statistically identified as different from controls (Table I ). The only statistically identified changes observed in mice were decreases in the serum glucose levels in high dose group males and triglyceride levels in females ingesting 5=15 mg/kg/day 1,3-D (Table 1) . With the possible exception of alkaline phosphatase levels, clinical chemistry changes in either species were consistent with the lower body weights and reduced nutritional status of affected animals. Postmortem data. Consistent with the depressed body weights of treated animals during the dosing period, terminal body weights of fasted rats at the mid and high dose levels and nonfasted mice at all dose levels were decreased 6-16 and 5-15% relative to controls, respectively (Tables 2 and  3) . A number of statistically identified organ weight changes were also observed in treated rats and mice (Tables 2 and  3 ). In general, absolute weights were decreased while organ to body weight ratios were increased consistent with the depressed body weights of these animals.
No gross pathologic lesions that were attributable to 1,3-D ingestion were observed at necropsy for rats or mice at any dose level. Decreased body fat was observed in most female rats ingesting 5=50 mg/kg/day 1,3-D following 13 weeks of dosing; however, this observation was also consistent with the depressed body weights of these animals.
The most significant histopathological change observed in either species ingesting 1,3-D was in the mucosa of the nonglandular portion of the stomach of rats. A minimal degree of basal cell hyperplasia was observed in both male and female rats at dosages of 3= 15 mg/kg/day 1,3-D (Table  4) . As shown in Fig. 4B , this effect was characterized by prominence of the basal or deepest layers of the mucosa due to increased cytoplasmic basophilia along with an apparent increased number of cell layers in the basilar portion of the mucosa. The normally round nuclei found in this location were oval with the long axis perpendicular to the basement membrane and were crowded together into a layer generally two to three cells thick rather than the single layer normally present. Additionally, there was a slight prominence of mononuclear cells at the basement membrane. These cells appeared to consist of endothelial, fibroblast, and inflammatory cells. Overall, basal cell hyperplasia was of minimal severity even at the high dosages. It is noteworthy that the nonglandular gastric mucosa of a control rat also had a very slight degree of basal cell hyperplasia. Basal cell hyperplasia of the mucosa of the nonglandular stomach was also observed following the 4-week recovery for rats; however, the severity was somewhat diminished compared to the 13-week findings, indicating the reversible nature of this lesion (Table 4) . Hyperkeratosis of the mucosa of the nonglandular stomach was also noted in several male and female rats ingesting 2*50 mg/kg/day and in a single male ingesting 15 mg/kg/ day 1,3-D (Table 4) . Also shown in Fig. 4b , this effect was characterized by a slight thickening of the most superficial layer of the nonglandular mucosa, the keratinized layer, suggesting a response to the potentially irritating 1,3-D. No effects were noted in the glandular portion of the gastric mucosa. Following the 4-week recovery period, no incidences of hyperkeratosis of the nonglandular stomach were noted.
Histologic changes were noted in the livers and kidneys of male mice ingesting 1,3-D (Table 4) ; however, these changes were considered secondary to the lowered body weights and reduced nutritional status of a majority of these animals. The liver change was observed in a number of male mice from all of the treatment groups and was characterized as a minimal, diffuse decrease in hepatocellular size consistent with decreased cytoplasmic glycogen. The kidney change was characterized as decreased vacuolation of tubular epithelial cells in a few males ingesting 175 mg/kg/day 1,3-D consistent with decreased cytoplasmic lipid content. There were no microscopic liver or kidney changes in female mice, although statistically identified decreases in absolute liver and kidney weights were noted in females ingesting 5=50 mg/ kg/day 1,3-D. Female mice normally appear to have less glycogen and cytoplasmic vacuolation in hepatocytes and renal tubular cells, respectively, upon microscopic examination, and therefore minimal changes are more difficult to recognize. DISCUSSION 1,3-D, a volatile and potentially unstable chemical, was successfully administered to rats and mice for 13 weeks by mixing a microencapsulated formulation of this chemical into animal feed. Analyses of test diets during the course of the study ensured that the microencapsulated 1,3-D was stable in feed and that test animals ingested targeted dosages of the test material. Additional work has shown that once ingested, microencapsulated 1,3-D is as readily absorbed as neat 1,3-D (W. Stott, unpublished data). Utilizing this technology, the oral dosages administered in the present study were in excess of those previously administered to rats and mice using bolus dosing (gavage), especially if the frequency of dosing is taken into consideration. Rats were administered up to only 30 mg/kg/day low purity 1,3-D for 5 days/week by Til et al. (1973) , while rats and mice were administered up to 50 and 100 mg/kg/day of higher purity 1,3-D, respectively, for only 3 days/week in the NTP (1985) gavage bioassay (Yang et al., 1986) , albeit for a much longer period of time.
The most significant treatment-related effect noted in rats or mice ingesting 1,3-D was a dose-related depression in body weights over much of the dosing period. In rats, doserelated decreases in feed consumption suggest a possible palatability problem with the test diets; however, a similar decrease was not noted in treated mice. The present study was not designed to unequivocally determine palatability of test diets (i.e., the preference of control over test diets); thus decreased feed consumption may simply have reflected decreased body weights. It is important to note that despite decreases in the feed consumption of some animals, correction of the concentration of 1,3-D in the diets ensured that target dosages were still maintained throughout the dosing period.
The only significant histopathological change noted in these animals was a minimal degree of hyperplasia and hyperkeratosis of the nonglandular stomach mucosa of roughly half the rats ingesting 3=50 mg/kg/day 1,3-D. These findings are consistent with the irritant properties of this chemical. Hyperplasia of the nonglandular stomach mucosa was also reported in rats administered 1,3-D via gavage in the NTP study within 9 months of dosing (NTP, 1985; Yang et al., 1986) . Further evidence of a portal of entry effect was noted in rats and mice administered inhaled 1,3-D vapors in which hyperplasia of the nasal mucosa was found to be a target tissue in these animals (Lomax et al., 1989; Stott et al., 1988) . Upon removal of the test material from the diet, some recovery from gastric mucosal lesions was observed in both sexes of rats.
The results of the mouse study contrast with those of earlier studies of 1,3-D in that the transitional epithelium of the urinary bladders of mice were not affected at dosages roughly 3-7 times higher than those causing significant hyperplasia and tumors, in the gavage B6C3F1 mouse study conducted by NTP, 50 or 100 mg/kg/day (NTP, 1985; Yang et al., 1986) . Obviously, the longer dosing duration of the latter study, even with a 3 days/week dosing regimen, could have affected lesion formation. However, a similar, significant degree of hyperplasia was noted in the urinary bladder mucosa of B6C3F1 mice inhaling >90 ppm 1,3-D vapor at a similar dosage and duration of dosing as in the present FIG. 4 . Photomicrographs of a section of the nonglandular ponion of the stomach of (A) a control male rat and (B) a male rat ingesting 100 mg/ kg/day 1,3-D for 13 weeks (H&E; 365x magnification). Note increased numbers of basal cells ([]) and slightly increased amounts of keratin (*) in the treated rat. study. Dosages administered in the latter study at 90-and 150-ppm exposure levels are calculated to have been approximately 160-210 and 260-350 mg/kg/day, respectively (5 days/week; assuming respiratory minute volumes 40-54 ml/ min and 80% absorption of vapor) (Chang et al., 1981; Guyton, 1947) . A possible explanation for this phenomenon may lie in differences in the levels of 1,3-D metabolites in the urine of mice. Stott et al. (1992) speculated that specific, species-specific breakdown products of glutathione conjugates of 1,3-D were responsible for bladder mucosa irritation and subsequent hyperplasia in mice. The concentration(s) of these products would be expected to reach higher levels following bolus (gavage) administration of 1,3-D or a 6-hr inhalation exposure than would occur during the more prolonged, yet lower, intake of 1,3-D during normal feeding. 1,3-D itself is not excreted in the urine of mice even at high bolus dosages (Dietz et al., 1984; J. Waechter, unpublished data) and is thus not believed to play a direct role in bladder mucosal effects (Stott et al, 1992 ).
In conclusion, nonbolus oral administration of 1,3-D to rats and mice was successfully conducted using microencapsulated 1,3-D added to the animal's diet. Treatment-related microscopic changes noted in treated animals were limited to portal-of-entry effects in the nonglandular stomach mucosa of rats consistent with the potential irritating properties of 1,3-D. The no-observed-adverse-effect level (NOAEL) for male rats, based upon minimal in-life body weight depression (=s6%), and the no-observed-effect level for female rats were determined to be 5 mg/kg/day. No specific target tissues were identified in mice; however, based on minimal body weight changes (*£5%), the NOAEL was determined to be 15 mg/kg/day in both sexes.
